Gilead Sales Up 18% in Q3, Thanks to Coronavirus Treatment Remdesivir

Gilead Sciences' (NASDAQ:GILD) product sales jumped 18% year over year in the third quarter thanks to its new coronavirus treatment, remdesivir, which goes by the brand name Veklury. Excluding the $873 million addition from remdesivir, sales would have been up a more modest 2%.